medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 3

<< Back Next >>

Gac Med Mex 2003; 139 (3)

Neuroblastoma: prognostic factors and survival. Experience in Hospital de Pediatr�a del Centro M�dico Nacional Siglo XXI and review of the literature..

López-Aguilar E, Cerecedo-Díaz F, Rivera-Márquez H, Valdéz-Sánchez M, Sepúlveda-Vildósola AC, Delgado HS, Vera-Hermosillo H, Vázquez-Langle JR, Wanzke AV

Language: Spanish
References: 32
Page: 209-214
PDF size: 55.82 Kb.


ABSTRACT

Neuroblastoma (NB) is the most frequent extracranial solid tumor in children according to the literature. In Mexico it is less frequent, fallin to 8th place. Our objective was to analyze our experience and compare it with the one reported in other countries. We included all patients admitted to our hospital during the previous five years and who had not received any treatment. Patients with stages I, II, and IV received cyclophosphamide and epirrubicin. Patients with stages were III and IV received the same chemotherapy alternating with cisplatinum., ifosfamide and etoposide during 12 months as well as massive doses of 131-MIBG and surgical ablation of the remaining tumor when possible. We included 30 patients, 25 with initial presentation in the abdomen. Five were in early stages and 20 (70%) were advanced with an overall survival of 100% and 27% at 5 years respectively. When analyzed by age, 40% were 12 months of age and 60% older, with survival of 100% and 27% in the same period, respectively. According to histology there was 91% survival for differentiated and 23% for undifferentiated tumors. The chemotherapeutic regimen reported is effective but not better than that reported by other authors, in which some benefits are seen with use of transplant and immunotherapy. The most important prognostic factors are still considered to be age, stage and histology.


REFERENCES

  1. Brodeur GM. Neuroblastoma and other peripheral neuroectodermal tumors. In: Fernbach DJ, Vietti TJ (eds): Clinical Pediatric Oncology, 4th. ed, p337. St Louis, Mosby Year book,1991.

  2. Fajardo CA, Mejía AM, Juárez OS, Rondón ME, Martínez GC. El cáncer, un problema de salud que se incrementa en el niño. Bol Med Hosp Infant Mex 2001:58:721-741.

  3. Fajardo JA, Mendoza SH, Valdéz ME, Mejía AM. Frecuencia de neoplasias malignas en niños atendidos en hospitales del DF. Bol Med Hosp Inf Mex 1996:53:57-66.

  4. Jerev B, Bretsky SS, Vogel R. Age and prognosis in neuroblastoma. Am J Pediatr Hematol Oncol 1984:6:233-138.

  5. Evans AE, Dänwio CJ, Propert K, Anderson J. Prognostic factors in neuroblastoma. Cancer 1927:59:1853-9.

  6. Breslow N, McCann B. Statistical estimation of prognosis for chiIdren with neuroblastoma. Cancer Res 1971:31:2092-2103.

  7. Siegel SE, Laug WE. Initial urinary catecholamine metabolites and prognosis in neuroblastoma. Pediatrics 1978; 62:77-87.

  8. Hogarty M, Maris J, White PS. Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Med Pediatr Oncol 2001; 36:52-55.

  9. Relationship between histopathological Features, MYCN Amplification and prognosis: A WPCCSC study. Med Pediatr Oncol 2001:36:169-176.

  10. Katzenstein HM, Salwen HR, Nguyen NN. Antiangiogenic therapy inhibits human neuroblastoma Growth. Med Pediatr Oncol 2001;36:190-193.

  11. Ladenstein R, Ambros IM, Potschger U, Amann G. Prognostic significance of DNA Di-Tetraploidy in neuroblastoma. Med Pediatr Oncol 2001;35:83-92.

  12. Brodeur GM, Seeger RC, Barret A. International criteria for diagnosis in patients with neuroblastoma. J Clinical Oncol 1922;6:1874.

  13. Evans AE, Dängio GJ, Randolph H. A proposed staging for childrens with neuroblastoma. Cancer 1971:27:374-372.

  14. Dawson DL, Trapp RG. Bioestadística médica. En: métodos para analizar datos de supervivencia. 1990:215-25. Ed. Appleton and Lange.

  15. Sackett DL, Haynes BH. Epidemiología clínica. Ed Panamericana 1994;255-275.

  16. Evans AE, Albo V, Dängio GJ. Factors Influencing survival of childrens with non metastatic neuroblastoma. Cancer 1976:32:661-666.

  17. Le Tourneau JN, Bernard JL, Hendren WH, Carcassone M. Evaluation of the role of surgery in 130 patients with neuroblastoma. J Pediatr Surg 1985;20:244-240.

  18. Haase GM, Wong KY, De Lorimier AM. Improvement in survival after excision of primary tumour in Stage III neuroblastoma. J Pediatr Surg 1989;24:194-200.

  19. Rubie H, Plantaz D, Coze C, Michon J. Localized and unresectable neuroblastoma in infants: Excellent outcome with primary chemoteraphy. Med Pediatr Oncol 2001: 36:247-250.

  20. Shafford E, Rogers DW, Pitchard J. Advanced neuroblastoma: improved response using a multidrug regimen (OPEC) including sequential cisplatinum and etoposido. J Clin Oncol 1984;2:742-747.

  21. Deborah AT, Pinkerton CR, Lewis IJ, Ellershaw C. OPEC/OJEC for stage IV neuroblastoma in children over one year of age. Med Pediatr Oncol. 2001:36:239-242.

  22. Yu LA, Eskenazi D, Strother R. A pilot study of anti-idiotype monoclonal antibody as tumor vaccine in patients with high risk neuroblastoma. Proc Am Soc Clin Oncol 2001:20. Abstract 1470.

  23. Kushner BH, Kramer M. Phase II trial of 3F8 monoclonal antibody and granulocite-macrophage colony stimulating factors for neuroblastoma. Proc Am Soc Clin Oncol 2001:20. Abstract 1471.

  24. Kushnmer, Kramer K, Meyers PA, Wollner N. Pilot study of Topotecan and high dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol 2000; 35:468-474.

  25. Cheung NK, Heller G. Chemotherapy doses intensity correlates strongly with response, median survival and median progression free survival in metastatic neuroblastoma. J Clin Oncol 1991;9:1050-1052.

  26. Goldie JH, Coldman AH. The somatic mutation theory of drug resistance: The “Goldie-Coldman” hypothesis revisted In: DeVita HP, editor. Cancer. Principles and practices of Oncology (3rd. Ed, Vol.3). Philadelphia.PA: J.B. Lippincott:1989. P1-22.

  27. Shimada H, Stram DO, Chatten J, et al. Identifications of subsets of neuroblastoma by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995:87:1470-1476.

  28. Garvin J, Bendit I, Nisen PD. N-myc oncogene expression and amplification in metastatic lesions of stage IV-s Neuroblastoma. Cancer 1990;65:2572-2575

  29. Tonini GP, Boni P, Pession A. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis. J Clin Oncol 1997;15:85-93.

  30. George RE, Variend E, Cullinane. Relationship between histopatholical features, MYCN amplification and prognosis. Med Pediatr Oncol 2001;36:169-176.

  31. Ambros PF, Ambros lM, Kerbl R, Luegmayr A, rumpler S. Intratumoral Heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med Pediatr Oncol 2001:36:1-4.

  32. Rudnick E, Khakoo Y, Antunes N, Seeger R, Brodeur G. Opsoclonos-myoclonus-ataxia syndrome in neuroblastoma: A report from the Children Cancer Group Study. Med Pediatr Oncol 2001;36:612-622.




2020     |     www.medigraphic.com